I'm with Digger65There are lots of cases where a small molecule can't replace a protein. For example, the mechanism of action of monoclonal antibodies which are having a big surge of late (e.g. MLNM's Campath or BGEN's hepatitis B vaccine)couldn't be replaced by a small molecule (as far as I can imagine).I would also add that the "ultimate goal" (as described by beachbum10) should include the stipulation of an orally available small molecule. Finding a peptide mimetic is a challenge in and of itself but making one that is orally bioavailable is an additional major challenge. However, therein lies the profit advantage over a protein therapeutic. Orally available drugs are in general: cheaper to make and much preferred by patients.Good BoardFS
Best Of |
Favorites & Replies |
Start a New Board |
My Fool |
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ra